PE22-28: What the Preclinical Research Shows

Research Use Only. Not for human or veterinary use. This article summarizes preclinical laboratory literature for educational reference and does not describe or suggest any use in people or animals.

PE22-28 is a short synthetic peptide that has drawn interest in neuroscience laboratories as a minimal, shortened analog of spadin. It sits within a small family of research peptides built around a single molecular target, the TREK-1 potassium channel. This overview gathers what the published preclinical literature reports about PE22-28, its chemistry, and how researchers handle it in the laboratory.

What is PE22-28

PE22-28 is a seven-amino-acid peptide derived from the sequence of spadin, which is itself a fragment released during the maturation of the protein sortilin (also called neurotensin receptor-3, or NTSR3). When sortilin is processed inside the cell, it releases a 44-amino-acid propeptide (PE). A 17-amino-acid portion of that propeptide, named spadin, was identified as a natural blocker of the TREK-1 channel. PE22-28 represents a much shorter seven-residue segment of that same region that laboratory studies have examined as a compact version retaining channel-blocking activity.

In simple terms, PE22-28 is studied as a research tool for probing the TREK-1 potassium channel, a two-pore-domain (K2P) channel that regulates the resting electrical state of neurons and other cells.

Where it sits in the research literature

Interest in the spadin family grew from work identifying TREK-1 as a molecular target relevant to mood regulation in animal models. Because spadin blocks TREK-1 and produced antidepressant-like readouts in rodent behavioral tests, research groups pursued shorter analogs such as PE22-28 to explore structure-activity relationships and improved stability. The literature on this family is preclinical, meaning it is based on cell systems and animal models rather than human clinical use.

Reported preclinical areas of study

• Blockade of the TREK-1 (K2P2.1) potassium channel in electrophysiology experiments.
• Antidepressant-like behavioral readouts in rodent models used to screen candidate molecules.
• Hippocampal neurogenesis as a downstream cellular readout in animal studies of the spadin family.
• Structure-activity work comparing spadin, shortened fragments, and retro-inverso analogs for potency and duration.
• TREK-1 expression in non-neuronal tissue, including pancreatic beta cells, as a broader question about the channel target.

Chemistry and notes at a glance

• Class: short synthetic peptide, spadin-derived fragment.
• Length: seven amino acid residues.
• Molecular target studied: TREK-1 / K2P2.1 two-pore-domain potassium channel.
• Parent molecule: spadin, a 17-residue fragment of the sortilin propeptide (PE).
• Typical laboratory form: lyophilized powder for reconstitution in a research setting.
• Storage: kept cold and dry, protected from light, in line with general peptide handling practice.

Why the research use only label matters

In the European Union, research chemicals such as PE22-28 are supplied strictly as laboratory reagents under a research use only designation. They are not medicines, are not approved for human or veterinary use, and carry no therapeutic claim. PE22-28 has not been approved by any medicines regulator and has not completed human clinical development. All published data referenced here come from in vitro and animal experiments. The research use only framework exists precisely so that these compounds can be supplied for legitimate laboratory work without being presented as treatments.

Handling and storage for researchers

General good practice for short peptides in a laboratory applies to PE22-28. Lyophilized material is typically stored frozen and kept sealed until needed. Researchers commonly reconstitute peptides in an appropriate research solvent and aliquot the working solution to limit repeated freeze-thaw cycles, which can degrade peptide integrity. Documenting lot number, certificate of analysis (COA), and HPLC purity supports reproducibility. For general reconstitution reference, see our notes on bacteriostatic water for peptide reconstitution.

Frequently asked questions

What is PE22-28 used for?

In the published literature, PE22-28 is used as a laboratory research tool to study the TREK-1 potassium channel and related cellular pathways in vitro and in animal models. It is supplied for research use only and is not for human or veterinary use.

How does PE22-28 relate to spadin?

PE22-28 is a shortened seven-residue analog derived from the spadin sequence. Spadin is a 17-residue fragment of the sortilin propeptide that blocks TREK-1. PE22-28 has been examined as a more compact version studied for the same channel target.

Is PE22-28 an approved drug?

No. PE22-28 is not an approved medicine anywhere. It has not been authorized by the European Medicines Agency or any other regulator, and the available data are preclinical only. It is offered strictly as a research chemical.

Is PE22-28 legal to buy for research in the EU?

PE22-28 is supplied within the EU as a laboratory reagent for research use only, not as a medicinal product. It is intended for qualified researchers and laboratory settings. Buyers are responsible for compliance with the applicable local rules governing the purchase and handling of research chemicals in their jurisdiction.

How should PE22-28 be stored?

As a general laboratory practice for peptides, PE22-28 is kept cold, dry, and protected from light, with reconstituted material aliquoted to reduce freeze-thaw cycles. This is handling guidance for laboratory material, not a use instruction.

Key takeaways

• PE22-28 is a short seven-residue peptide derived from spadin and studied as a TREK-1 potassium channel blocker.
• The published literature is preclinical, based on cell and animal models, and centers on the spadin family and the TREK-1 target.
• PE22-28 is not an approved drug and is supplied for research use only, not for human or veterinary use.
• Standard peptide handling applies: cold, dry, dark storage and careful documentation of COA and purity.

Related research overviews: Selank, Semax, and DSIP. Browse available research materials in our full catalog.

References

References sourced via PubMed.

1. Mazella J, Borsotto M, Heurteaux C. The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1. Front Pharmacol. 2019;9:1541. https://doi.org/10.3389/fphar.2018.01541 | https://pubmed.ncbi.nlm.nih.gov/30670975/
2. Veyssiere J, Moha Ou Maati H, Mazella J, et al. Retroinverso analogs of spadin display increased antidepressant effects. Psychopharmacology (Berl). 2015;232(3):561-574. https://doi.org/10.1007/s00213-014-3683-2 | https://pubmed.ncbi.nlm.nih.gov/25080852/

Disclaimer: This content is provided for informational and research reference purposes only. PE22-28 is sold as a research chemical for laboratory use only and is not for human or veterinary use. Nothing here is medical advice or a therapeutic claim, and no use in humans or animals is described or encouraged.